查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球外陰陰道念珠菌病藥物市場：市場規模-藥物類別、給藥途徑、分銷渠道、區域展望、競爭戰略、細分市場預測 (-2032)
市場調查報告書
商品編碼
1182446

全球外陰陰道念珠菌病藥物市場：市場規模-藥物類別、給藥途徑、分銷渠道、區域展望、競爭戰略、細分市場預測 (-2032)

Vulvovaginal Candidiasis Treatment Market Size- By Drug Class, By Route of Administration, By Distribution Channel- Regional Outlook, Competitive Strategies and Segment Forecast to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 239 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

到 2032 年，全球外陰陰道念珠菌病藥物市場規模預計將達到 16.2 億美元，複合年增長率為 4.61%。

外陰陰道念珠菌病患病率上升、批准新藥以滿足未滿足的需求以及政府和非營利組織為提高認識所做的努力是市場增長的主要驅動力。.

本報告考察了全球外陰陰道念珠菌病藥物市場，涵蓋市場動態、市場變量和前景、競爭格局、按藥物類別劃分的市場分析、給藥途徑、分銷渠道和地區、公司概況等。我們提供信息。

內容

第一章介紹

  • 調查範圍
  • 市場細分分析

第二章研究方法論

  • 調查數據來源
  • 市場規模估計
  • 數據三角測量

第 3 章執行摘要

第四章市場動態

  • 分析驅動因素、制約因素、機遇和挑戰
    • 司機
    • 約束因素
    • 機會
    • 任務
  • COVID-19 對全球外陰陰道念珠菌病藥物市場的影響

第五章市場變數與展望

  • SWOT 分析
    • 強度
    • 弱點
    • 機會
    • 威脅
  • PESTEL 分析
    • 政治形勢
    • 經濟狀況
    • 社交情況
    • 技術
    • 環境狀況
    • 法律狀況
  • 波特的五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭對手之間的敵對關係
  • 熱圖分析

第六章競爭格局

  • 全球治療外陰陰道念珠菌病生產基地分佈、銷售區域、產品種類
  • 全球外陰陰道念珠菌病藥物市場的併購、合作夥伴關係、產品發布和協作

第 7 章。全球外陰陰道念珠菌病藥物市場：按藥物類別（2019-2032，百萬美元）

  • 克黴唑
  • 氟康唑
  • 酮康唑
  • 制黴菌素
  • 特比□芬
  • 特康唑
  • 其他

第 8 章。全球外陰陰道念珠菌病市場：按給藥途徑（2019-2032，百萬美元）

  • 靜脈注射
  • 口語
  • 本地

第 9 章。全球外陰陰道念珠菌病藥物市場：按分銷渠道（2019-2032，百萬美元）

  • 醫院藥房
  • 在線藥店
  • 零售藥房

第 10 章全球外陰陰道念珠菌病藥物市場：按地區（2019-2032，百萬美元）

  • 全球各地區外陰陰道念珠菌病藥物市場規模和市場份額（2019-2025 年）
  • 全球各地區外陰陰道念珠菌病藥物市場規模和市場份額（2026 年至 2032 年）
  • 亞太地區
    • 澳大利亞
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 歐洲
    • 法國
    • 德國
    • 意大利
    • 西班牙
    • 英國
    • 其他歐洲
  • 中東和非洲
    • 沙特阿拉伯王國
    • 阿拉伯聯合酋長國
    • 其他中東和非洲地區
  • 北美
    • 加拿大
    • 墨西哥
    • 美國
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他南美洲

第11章公司簡介

  • 安斯泰來製藥公司
    • 公司簡介
    • 財務展望
    • 產品概述
    • 最近的發展
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals
  • Grupo Ferrer International S.A.
  • Mycovia Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Scynexis, Inc.

第12章縮略語列表

第 13 章參考鏈接

第14章結論

第 15 章範圍

簡介目錄
Product Code: PHAR2214

Global Vulvovaginal Candidiasis Treatment Market Overview:

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.

The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy. The size of the global market for vulvovaginal candidiasis treatments is anticipated to increase. An NCBI article claims that VVC is a frequent virus in women that affects millions of women annually all over the world. Rising illness burden, a strong growing pipeline with recent approvals of disease management medicines, and the introduction of novel pharmaceuticals like BREXAFEMME and VIVJOA are some of the main reasons propelling market growth.The rising prevalence of VVC disease, the approval of novel medications that can address unmet needs, and initiatives by the government and non-profit groups to raise awareness are some of the major drivers of business growth.

Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market:

The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals. The market for vulvovaginal candidiasis has quickly rebounded as a result of all these factors, and it is expected to keep expanding.

Scope of the Report:

  • Market size available for years: 2019-2032
  • Base year considered: 2021
  • Forecast period: 2022-2032
  • Segments covered: By Drug Class, By Route of Administration, By Distribution Channel
  • Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa
  • Companies Covered: Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc.

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

  • By Drug Class: Based on the Drug Class, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Clotrimazole, Fluconazole, Ketoconazole, Nystatin, Terbinafine, Terconazole, Others.
  • By Route of Administration: Based on the Route of Administration, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Intravenous, Oral, Topical.
  • By Distribution Channel: Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.
  • By Region: The global industry was dominated by North America. The area is anticipated to continue to grow steadily during the projection period, maintaining its leadership position. High disease prevalence, rising patient awareness, rising healthcare costs, and the existence of significant players in the area can all be contributed to this dominance. The development of the regional market is also aided by new approvals, launches, and innovative government initiatives. Asia Pacific, on the other hand, is anticipated to experience the fastest growth rate during the anticipated years. The increased disease burden of VVC and rising testing rates are both responsible for the high growth rate. Positive developments include government healthcare coverage, increasing consumer awareness, and a desire to use medical services.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Competitive Landscape

  • 6.1 Global Vulvovaginal Candidiasis Treatment Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market

7. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2019-2032 (USD Million)

  • 7.1 Clotrimazole
  • 7.2 Fluconazole
  • 7.3 Ketoconazole
  • 7.4 Nystatin
  • 7.5 Terbinafine
  • 7.6 Terconazole
  • 7.7 Others

8. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2019-2032 (USD Million)

  • 8.1 Intravenous
  • 8.2 Oral
  • 8.3 Topical

9. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

  • 9.1 Hospital Pharmacy
  • 9.2 Online Pharmacy
  • 9.3 Retail Pharmacy

10. Global Vulvovaginal Candidiasis TreatmentMarket, By Region, 2019-2032 (USD Million)

  • 10.1 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2019-2025)
  • 10.2 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2026-2032)
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Europe
    • 10.4.1 France
    • 10.4.2 Germany
    • 10.4.3 Italy
    • 10.4.4 Spain
    • 10.4.5 United Kingdom
    • 10.4.6 Rest of Europe
  • 10.5 Middle East & Africa
    • 10.5.1 Kingdom of Saudi Arabia
    • 10.5.2 United Arab Emirates
    • 10.5.3 Rest of Middle East & Africa
  • 10.6 North America
    • 10.6.1 Canada
    • 10.6.2 Mexico
    • 10.6.3 United States
  • 10.7 Latin America
    • 10.7.1 Argentina
    • 10.7.2 Brazil
    • 10.7.3 Rest of South America

11. Company Profiles

  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Company details
    • 11.1.2 Financial outlook
    • 11.1.3 Product summary
    • 11.1.4 Recent developments
  • 11.2 Basilea Pharmaceutica Ltd.
    • 11.2.1 Company details
    • 11.2.2 Financial outlook
    • 11.2.3 Product summary
    • 11.2.4 Recent developments
  • 11.3 Bayer AG
    • 11.3.1 Company details
    • 11.3.2 Financial outlook
    • 11.3.3 Product summary
    • 11.3.4 Recent developments
  • 11.4 Bristol-Myers Squibb Company
    • 11.4.1 Company details
    • 11.4.2 Financial outlook
    • 11.4.3 Product summary
    • 11.4.4 Recent developments
  • 11.5 Cadila Pharmaceuticals
    • 11.5.1 Company details
    • 11.5.2 Financial outlook
    • 11.5.3 Product summary
    • 11.5.4 Recent developments
  • 11.6 Grupo Ferrer International S.A.
    • 11.6.1 Company details
    • 11.6.2 Financial outlook
    • 11.6.3 Product summary
    • 11.6.4 Recent developments
  • 11.7 Mycovia Pharmaceuticals, Inc.
    • 11.7.1 Company details
    • 11.7.2 Financial outlook
    • 11.7.3 Product summary
    • 11.7.4 Recent developments
  • 11.8 Pfizer, Inc.
    • 11.8.1 Company details
    • 11.8.2 Financial outlook
    • 11.8.3 Product summary
    • 11.8.4 Recent developments
  • 11.9 Scynexis, Inc.
    • 11.9.1 Company details
    • 11.9.2 Financial outlook
    • 11.9.3 Product summary
    • 11.9.4 Recent developments

12. List of Abbreviations

13. Reference Links

14. Conclusion

15. Research Scope